Concepedia

Evan Friedman

EF

12

Publications

599

Citations

11

H-Index

2006

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Western University

Rutgers Cancer Institute

Evan Friedman is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

2006–2024

12

Publications

12

A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer

Eric H. Rubin, Nancy Agrawal, Evan Friedman et al. · Clinical Cancer Research · 2006 · 113 citations · Full text

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial

Dirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang et al. · The Lancet HIV · 2020 · 88 citations

, , +8

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Larissa Wenning, Evan Friedman, James Kost et al. · Antimicrobial Agents and Chemotherapy · 2008 · 72 citations · Full text

Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics

Diana M. Brainard, Evan Friedman, Bo Jin et al. · The Journal of Clinical Pharmacology · 2010 · 54 citations

, , +5

A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer

Pamela N. Münster, Eric H. Rubin, Simon Van Belle et al. · Clinical Cancer Research · 2009 · 48 citations

Rows per page

1–5 of 12